Synthetically re-designing eukaryotic metabolism has proven immensely challenging, raising the question of whether evolution has metabolically hardwired eukaryotic cells. Yu et al. now report that, through orchestrating multiple genetic changes and laboratory evolution, Saccharomyces metabolism can be reprogrammed from its evolutionary objective of producing ethanol to produce large amounts of free fatty acids.
Imagine you want to reconfigure your diesel car into one using gasoline. This can be achieved by swapping the engine. Now imagine you need to do the same while driving on the highway. This situation demonstrates what differentiates metabolic/biological engineering from engineering in other disciplines. It requires intervening in a system of hundreds of intertwined, finely balanced, and co-regulated reactions-many directly linked to essential cellular functions-all while cells remain alive and metabolically active. Consequently, the more complex the metabolic network or its regulation, the more difficult the task. Indeed, a eukaryotic host like Saccharomyces cerevisiae has proven harder to engineer than prokaryotes, begging the question: has the evolution of eukaryotic complexity led to more rigid metabolism? In this issue of Cell, Yu et al. (2018) use a combination of precise genetic engineering and laboratory evolution to demonstrate that budding yeast metabolism can in fact be reconfigured to produce fatty acids rather than ethanol-and at extremely high titers (Figure 1) .
S. cerevisiae rapidly and efficiently converts sugars to ethanol. Indeed, this feature has been fundamental to the integration of yeast in the lifestyle of several civilizations and led to the early domestication of these single-celled eukaryotes (Gallone et al., 2016) . Thanks to the same feature, yeast is likely to play another key role in modern society as the platform for sustainable biofuel production. A typical fermentation process produces around 45 g of alcohol per 100 g of glucose-very close to a theoretical yield of 50%. At first, this seemingly wasteful production appears to be a poor evolutionary choice. However, from an ecological perspective, exporting ethanol offers several advantages, including achieving high sugar-uptake rates (and diverting resources away from competitors), inhibiting bacterial growth, and the ability to reuse the carbon from ethanol once sugars are exhausted. However, this ecological model can only explain how this alcohol ''addiction'' came to be selected for and not the underlying physical and chemical constraints, which enabled ethanol production in the first place.
These physical and chemical constraints underlie the topological organization of metabolic networks and are the ones that make the task of a metabolic engineer difficult. First, ethanol excretion is enabled as part of overflow metabolism, driven by the need to maintain the redox and carbon balance of the cell. Moreover, metabolic network topologies are restricted by structural properties that emerge from key operating principles of metabolism (bio)chemical cross-talk and resource allocation. Because metabolites are small and made from a limited set of moieties, there is extensive cross-inhibition between enzymes and distal metabolites; therefore, the lower the concentration and diversity of metabolic intermediates, the less self-inhibited metabolism is (Alam et al., 2017) . This feature provides further advantage for overflow metabolism, as exported metabolites can be re-imported by neighboring cells, allowing these to make use of metabolites without biosynthetic burden (Ponomarova et al., 2017) . Finally, competition between enzymes for already crowded cellular space means that a route with lower energy yield can become optimal (Nilsson and Nielsen, 2016) . Importantly, such structural constraints manifest only once the biochemical reactions assemble in the crowded cellular network and are therefore difficult to quantify in experiments that study a single reaction in isolation. They are, however, important, as underlined by an organic chemistry-based attempt to reconstruct early metabolic pathways one reaction at a time, which resulted in a chemical network in which not a single intermediate resembled metabolism (Sutherland, 2016) .
For budding yeast, it proved an efficient solution to sacrifice carbon equivalents and excrete ethanol in order to run a smaller and well-balanced network. Ethanol production, of course, is not the only route that a metabolic network can take. Analogously, mammalian cells excrete lactate in a metabolic balancing process, and so-called oleaginous yeasts divert a large part of their carbon flux into the production of fatty acids and lipids (Sitepu et al., 2014) . In this paper, Yu and colleagues speculated that the metabolism of the oleaginous yeasts could serve as a ''blueprint'' to reconfigure the ethanol-producing S. cerevisiae to completely change its metabolic output while keeping the metabolic network balanced.
To achieve this goal, the authors executed two key steps, each of which required multiple orchestrated genetic modifications. First, oleic yeast-like metabolic pathways were introduced to enhance the production capacity for free fatty acids (FFAs), specifically by increasing the supply for acetyl-coenzyme A (CoA) via ATP-citrate lyase and increasing NADPH production in the oxidative pentose phosphate pathway while simultaneously deleting the enzymes responsible for FFA catabolism. Once this module was in place, the ethanol production of Saccharomyces could be abolished without creating a fatal redox imbalance, ultimately allowing for the creation of a synthetic oil yeast that produces FFAs at a previously unachieved yield of 30 g/L. Specifically, ethanol production was prevented through depletion of two pyruvate decarboxylase subunits, causing the cells to cease formation of acetaldehyde, the substrate for alcohol dehydrogenases. However, an additional key obstacle had to be overcome: this mutant was inviable when grown on glucose.
To address this problem, no blueprint was available. Instead, the authors turned to an adaptive evolution strategy, which revealed a familiar player in the coordination of glucose metabolism and redox balance: pyruvate kinase. All adapted strains lost the highly active pyruvate kinase isoform PYK1, enforcing a shift of flux through the alternative isoform PYK2, with lower specific activity. This mechanism is intrinsically activated to balance the redox state when shifting between fermentative and oxidative metabolism (Grü ning et al., 2011) . It thus played in the authors' favor that the inviability of PDC triple mutants was explained by redox imbalance rather than by the lack of any single product. Thus, after synthetic reprogramming toward FFA production, adaptive evolution allowed the cells to hijack a pre-existing metabolic module to repair a fatal redox imbalance.
Beyond the impressive bioengineering feat, what did we learn for biology? Metabolic plasticity is maintained in complex organisms; however, the metabolic network is not only embedded in regulatory layers, but also so intertwined that even supposedly moderate metabolic re-design tasks require a large number of orchestrated adaptive changes. Once identified and introduced, however, these modifications allow the engineering of strains that can be of immense use in industrial production and may lead to the downstream achievement of environmentally sustainable production cycles that we need to envisage in the decades to come.
We should mention that the reprogramming of S. cerevisiae to become an oil yeast did not require the addition of metabolic reactions that would be entirely new to the yeast clade, nor did it require altering the topological organization of the metabolic network or the invention of new enzymes. It is important to note that the mammoth endeavor of redesigning yeast metabolism was successful because adaptive evolution could access an ''off-the-shelf'' solution (the PYK1/PYK2 system) to achieve redox balance. In a way, the success story from Yu and colleagues-while representing a huge step forward-thus also illustrates how far we actually are from the design of truly new metabolic capacities, which remains difficult for reasons such as structural cross-interference between the hundreds of small molecules and enzymes that constitute the metabolome in a densely cross-dependent network that we are just beginning to understand.
Figure 1. Reconfiguring the Metabolism of a Eukaryotic Cell
A combination of metabolic engineering and adaptive evolution enabled Yu et al. to redirect carbon flux in S. cerevisiae away from its hallmark ethanol production to free fatty acids, effectively converting it to an oil yeast. This remarkable engineering was achieved by taking advantage of the modular, redox-centered organization of the yeast metabolic network. Precision genetic engineering was used to introduce a metabolic module that produces high quantities of free fatty acids, and the intrinsic ethanol production capacity was removed by abolishing pyruvate decarboxylase activity. An adaptive evolution experiment solved the final hurdle (inviability on glucose) via hijacking of yeast's intrinsic PYK1/PYK2 system to restore redox balance and resulted in the desired high producer strain.
Altered cell metabolism is ubiquitous in cancer cells; however, it remains challenging to exploit these alterations for cancer therapy. A new study reveals that metabolic alterations to the urea cycle promote tumor growth but unexpectedly also trigger mutations that mark cancer cells for recognition by immunotherapy.
Cancer cells have altered metabolic demands compared to the normal cells from which they arise. Aberrant proliferation in cancer cells necessitates changes in metabolic fluxes to support increased biosynthesis of nucleotides, proteins, and lipids to generate cell biomass and divide. Since the repertoire of metabolic enzymes in cancer cells is predominantly the same as in their parental cells, altered cancer metabolism is primarily driven by changes in nutrient uptake, altered enzyme expression, and signalingdependent regulation of enzyme activities (Vander Heiden and DeBerardinis, 2017) . Understanding how specific metabolic alterations benefit tumor growth, as well as the liabilities that accompany these alterations, is critical to improve cancer therapy. In this issue of Cell, Lee et al., (2018) observe pervasive changes to the expression of urea cycle enzymes across tumor types and identify an unforeseen genetic consequence that can sensitize these cancers to immunotherapy.
One burgeoning metabolic alteration in cancer is modifications in urea cycle activity. While the classically described urea cycle is active in the liver and kidney where it functions in organismal nitrogen disposal, other tissues express many urea cycle enzymes. Altered expression of these enzymes occurs in cancer-for example, argininosuccinate synthetase 1 (ASS1) expression is decreased in many tumors compared to parental tissues (Delage et al., 2010) . Decreased ASS1 expression enhances cancer cell proliferation by preventing the consumption of aspartate, a substrate of ASS1, allowing it to be diverted into biosynthetic pathways including pyrimidine nucleotide synthesis ( Figure 1A ) (Rabinovich et al., 2015) . Cancer cells with suppressed ASS1 expression form tumors that grow at a faster rate, suggesting that aspartate levels and pyrimidine synthesis can be endogenous metabolic limitations for tumor growth. Indeed, other methods to increase cancer cell aspartate acquisition can also increase tumor growth (GarciaBermudez et al., 2018; Sullivan et al., 2018) , further supporting the hypothesis that adaptations that preserve aspartate are selected for because they confer a proliferative advantage. However, the extent of dysregulated urea cycle enzyme expression across tumor types, and the metabolic consequences of these changes, have not been broadly characterized.
Since the urea cycle has several linear steps, it is possible to modulate urea cycle function by changes in activity at several points in the pathway. In their study, Lee and colleagues measured expression changes of several urea cycle enzymes across a wide range of cancer types. Impressively, cancers typically had at least one, and usually several, alterations to the expression of urea cycle components in the direction that will promote cytosolic aspartate availability and carbamoyl-phosphate production, enabling increased pyrimidine synthesis ( Figure 1A ) (Kim et al., 2017) . Since the specific urea cycle alterations are not uniform across tumor types, the authors aggregated these changes into a urea cycle dysregulation (UCD) score to compare how the net change to the urea cycle, regardless of the specific components affected, can impact tumor growth ( Figure 1B) . In human tumor samples,
